Warren Whitehead - 05 Feb 2024 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)

Reporting relationship
Director
Issuer ticker
APTOF
Reported as of
05 Feb 2024
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
07 Feb 2024, 16:33:48 UTC
Prior SEC filing
23 Jan 2023
Next SEC filing
01 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Warren Whitehead

Key filing fact

Warren Whitehead filed Form 4 for Aptose Biosciences Inc. (APTOF) on 07 Feb 2024.

Key facts

  • This page summarizes Warren Whitehead's Form 4 filing for Aptose Biosciences Inc. (APTOF).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 07 Feb 2024, 16:33.

Change

  • Previous filing in this sequence was filed on 23 Jan 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APTO transaction Derivative

Director Stock Options (Right to Buy)

Award

Transaction value
$0
Shares
+3,333
Change %
Price
$0.000000
Shares after
3,333
Date
05 Feb 2024
Ownership
Direct
Underlying class
Common Shares
Underlying amount
3,333
Exercise price
$1.97
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Converted from Canadian exercise price of C$2.67 using an exchange rate of C$1.3527 = US$1.00.

Footnote F2

The options vest as follows: 50% on February 5, 2025; 25% on February 5, 2026; and 25% on February 5, 2027.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .